Taiho

News

Taiho's late-stage Duchenne candidate fails trial

Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

News

Merck & Co joins KRAS gold rush with Taiho and Astex collabo...

US-based Merck & Co has forged an R&D tie-up with Taiho and Astex Pharmaceuticals, focused on developing small molecule drugs targeting the KRAS gene that has become the subject of

Taiho's late-stage Duchenne candidate fails trial

Taiho snaps up ADC partner Araris for up to $1.14bn

Merck & Co joins KRAS gold rush with Taiho and Astex collabo...

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks